PATHWAY TO RESULTS

As global leaders in CNS, we’re creating new possibilities for faster and more reliable signal detection in clinical trials.

Learn More

SCIENCE AND TECHNOLOGY WIRED TOGETHER

Connecting the latest clinical science with groundbreaking technology, we offer the most versatile, reliable, and secure eCOA solutions available.

Learn More

SIMPLICITY IS KEY

Our services are designed to bring simplicity to complex and demanding clinical trials.

Learn More

SOLVING THE PUZZLE OF ALZHEIMER’S DISEASE

Our instruments are sensitive to subtle cognitive changes in at-risk and early AD populations.

Learn More

A PATHWAY TO RESULTS

As global leaders in the CNS field, we’re creating new possibilities for faster, more reliable signal detection in clinical trials.

Learn More

DR. LUCA PANI JOINS NEUROCOG TRIALS

Former Director General of The Italian Medicines Agency (AIFA) Dr. Luca Pani Joins NeuroCog Trials

Read More

SCIENCE AND TECHNOLOGY WIRED TOGETHER

Connecting the latest clinical science with groundbreaking technology, we offer the most versatile, reliable, and secure eCOA solutions available.

Learn More

SIMPLICITY IS KEY

Our services are designed to bring simplicity to complex and demanding clinical trials.

Learn More

SOLVING THE PUZZLE OF ALZHEIMER’S DISEASE

Our instruments are sensitive to subtle cognitive changes in at-risk and early AD populations.

Learn More

Powerful Solutions for Clinical Trials

eSolutions

We offer a suite of eSolutions designed to optimize the assessment of cognitive, clinical, and functional outcomes.

Clinical Trials

Our clinical trials services ensure the highest quality of data collection and improve trial performance from start-up to close-out.

Expertise

Our team of scientists, clinicians, and advisors have wide-ranging expertise across multiple therapeutic areas.

From Our Co-Founder and CEO

“I see this as a pivotal time in the field of drug development and the assessment of symptoms, cognition and functioning. Technological advances are offering the potential to increase signal intensity, reduce costs, and allow sites and raters to do their jobs with greater ease. This is also a pivotal time for NeuroCog to extend the wealth of knowledge generated from innovative scientific advances and apply them to the clinical trials community.”

Richard Keefe, PhD, Co-Founder and CEO

From Our Co-Founder and CEO

“I see this as a pivotal time in the field of drug development and the assessment of symptoms, cognition and functioning. Technological advances are offering the potential to increase signal intensity, reduce costs, and allow sites and raters to do their jobs with greater ease. This is also a pivotal time for NeuroCog to extend the wealth of knowledge generated from innovative scientific advances and apply them to the clinical trials community.”

Richard Keefe, PhD, Co-Founder and CEO

Featured Resources and Tools

NCT Pathway

Bridging the Gap between Science and Technology

NCT Pathway is a fully customizable eCOA platform  designed to accommodate multiple cognitive, clinical, and functional outcome measures. Pathway streamlines data collection, improves the quality of results, and provides seamless and secure data transfer.

BAC App

Brief Assessment of Cognition App

The iPad®-based BAC App provides digital recording of data, audio recordings of verbally-delivered responses, and examiner-recorded data for post-test verification of responses. Using the BAC App provides many of the benefits around cost-effectiveness and improved test reliability.

VRFCAT

Virtual Reality Functional Capacity Assessment Tool

The Virtual Reality Functional Capacity Assessment Tool is a computerized measure that was developed to be a reliable, valid, and sensitive measure of functional capacity, with the potential to demonstrate real-world functional improvements associated with cognitive change.

SCoRS

Schizophrenia Cognition Rating Scale

SCoRS is currently being used as a co-primary endpoint in several international phase 2 and phase 3 trials assessing cognitive treatment change in schizophrenia, and has been permitted by the FDA for pivotal registration trials. It has excellent test-retest reliability, strong relation to cognitive performance, and proven sensitivity to treatment.